1-Year Follow up to the 1473-IMIQ Study

Graceway Pharmaceuticals

Status: Completed

Conditions: Keratosis

Treatments: Drug: Imiquimod 5% cream

Study type: Observational

Funder types: Industry

Identifiers

NCT00114023

1518-IMIQ

Details and patient eligibility

About

This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subject had to participate in the 1473-IMIQ Study AND have had 100% clearance of AK lesions

Exclusion criteria

• Did not use any topical preparations in the previous treatment area within 24-hours of the scheduled visit.